April 4, 2017 /
MS Drug Therapies
Click here to receive MS news via e-mail
European News
AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. today announced that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for (glatiramer acetate injection) COPAXONE® 40 mg/ml 3 times weekly. The product was originally authorized through a decentralized procedure in Europe. An equivalent change has already been approved for COPAXONE® 20 mg/ml in December 2016.
According to the European Multiple Sclerosis Platform (EMSP) around 700,000 people in Europe are affected by Multiple Sclerosis (MS), with a 2:1 ratio between women and men. MS is more common among women of childbearing age compared with any other age group with the average age of diagnosis approximately 30 years, with ~43% of the women starting a family after diagnosis.
The removal of the pregnancy contraindication follows a Positive Variation Assessment Report issued by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA; Reference Member State), and agreed by all Concerned Member States (CMS) in Europe, that were involved in the procedure. Granting of national approvals by all involved EU Member States will happen in the near future. COPAXONE® is indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS).
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
Categories
Latest Blog Posts
- People Wait an Average of 50 Days to See a Neurologist, and People with MS Wait Even Longer: What Can We Do to Improve Access to MS Care?
- Key Findings on GLP-1 Use in MS
- Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
- Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
- This Blood Test Tracks MS Activity? (Octave Explained)
- Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
- Will Medicare Pay for a Mobility Scooter?
- Vagus nerve stimulation (VNS)
- Vitamin D Deficiency in Adults: Symptoms, Treatments, and Related Health Conditions
- How to Get Through an MRI if You’re Claustrophobic
- How MS Can Affect Your Oral Health
- Signs of multiple sclerosis show up in blood years before symptoms, study finds
- MS patients less likely to have Alzheimer’s, study finds
- APOE4 gene variant linked to greater nerve damage in MS: Study
- High Epstein-Barr antibody levels over time may aid MS diagnosis
- Stopping Ocrevus in stable MS doesn’t seem to raise 2-year risk, study finds
- Online Survey: Stress and MS – from the National MS Society
- High-Altitude Gene Helps Heal Myelin Damage
- Talking Biosimilars – Unlocking Patient access through coordinated action
- Beyond One Drug: What the Tolebrutinib Decision Teaches Us About Progressive MS Trials.
